Literature DB >> 12930145

Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors.

Giuseppe Campiani1, Stefania Butini, Francesco Trotta, Caterina Fattorusso, Bruno Catalanotti, Francesca Aiello, Sandra Gemma, Vito Nacci, Ettore Novellino, Jennifer Ann Stark, Alfredo Cagnotto, Elena Fumagalli, Francesco Carnovali, Luigi Cervo, Tiziana Mennini.   

Abstract

The synthesis, pharmacological evaluation, and structure-activity relationships (SARs) of a series of novel arylalkylpiperazines structurally related to BP897 (3) are described. In binding studies, the new derivatives were tested against a panel of dopamine, serotonin, and noradrenaline receptor subtypes. Focusing mainly on dopamine D(3) receptors, SAR studies brought to light a number of structural features required for high receptor affinity and selectivity. Several heteroaromatic systems were explored for their dopamine receptor affinities, and combinations of synthesis, biology, and molecular modeling, were used to identify novel structural leads for the development of potent and selective D(3) receptor ligands. Introduction of an indole ring linked to a dichlorophenylpiperazine system provided two of the most potent and selective ligands known to date (D(3) receptor affinity in the picomolar range). The intrinsic pharmacological properties of a subset of potent D(3) receptor ligands were also assessed in [(35)S]-GTPgammaS binding assays. Evidence from animal studies, in particular, has highlighted the dopaminergic system's role in how environmental stimuli induce drug-seeking behavior. We therefore tested two novel D(3) receptor partial agonists and a potent D(3)-selective antagonist in vivo for their effect in the cocaine-seeking behavior induced by reintroduction of cocaine-associated stimuli after a long period of abstinence, and without any further cocaine. Compound 5 g, a nonselective partial D(3) receptor agonist with a pharmacological profile similar to 3, and 5p, a potent and selective D(3) antagonist, reduced the number of active lever presses induced by reintroduction of cocaine-associated stimuli. However, 5q, a highly potent and selective D(3) partial agonist, did not have any effect on cocaine-seeking behavior. Although brain uptake studies are needed to establish whether the compounds achieve brain concentrations comparable to those active in vitro on the D(3) receptor, our experiments suggest that antagonism at D(2) receptors might significantly contribute to the reduction of cocaine craving by partial D(3) agonists.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12930145     DOI: 10.1021/jm0211220

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  26 in total

Review 1.  The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence.

Authors:  Christian A Heidbreder; Eliot L Gardner; Zheng-Xiong Xi; Panayotis K Thanos; Manolo Mugnaini; Jim J Hagan; Charles R Ashby
Journal:  Brain Res Brain Res Rev       Date:  2005-07

2.  High-affinity and selective dopamine D₃ receptor full agonists.

Authors:  Jianyong Chen; Beth Levant; Shaomeng Wang
Journal:  Bioorg Med Chem Lett       Date:  2012-07-11       Impact factor: 2.823

Review 3.  Rationale in support of the use of selective dopamine D₃ receptor antagonists for the pharmacotherapeutic management of substance use disorders.

Authors:  Christian Heidbreder
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-10-28       Impact factor: 3.000

4.  An endogenous neuroprotectant substance, 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ), prevents the behavioral and neurochemical effects of cocaine reinstatement in drug-dependent rats.

Authors:  L Antkiewicz-Michaluk; M Filip; J Michaluk; I Romańska; E Przegaliński; J Vetulani
Journal:  J Neural Transm (Vienna)       Date:  2006-08-10       Impact factor: 3.575

5.  Synthesis and initial evaluation of [11C](R)-RWAY in monkey-a new, simply labeled antagonist radioligand for imaging brain 5-HT1A receptors with PET.

Authors:  Julie A McCarron; Sami S Zoghbi; H Umesha Shetty; Eric S Vermeulen; Håkan V Wikström; Masanori Ichise; Fumihiko Yasuno; Christer Halldin; Robert B Innis; Victor W Pike
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06-20       Impact factor: 9.236

6.  Blockade of mesolimbic dopamine D3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats.

Authors:  Zheng-Xiong Xi; Jeremy Gilbert; Arlene C Campos; Nicole Kline; Charles R Ashby; Jim J Hagan; Christian A Heidbreder; Eliot L Gardner
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

7.  The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats.

Authors:  Krista Spiller; Zheng-Xiong Xi; Xiao-Qing Peng; Amy H Newman; Charles R Ashby; Christian Heidbreder; József Gaál; Eliot L Gardner
Journal:  Psychopharmacology (Berl)       Date:  2007-11-06       Impact factor: 4.530

8.  Design, synthesis, and evaluation of bitopic arylpiperazine-phthalimides as selective dopamine D3 receptor agonists.

Authors:  Yongkai Cao; Ningning Sun; Jiumei Zhang; Zhiguo Liu; Yi-Zhe Tang; Zhengzhi Wu; Kyeong-Man Kim; Seung Hoon Cheon
Journal:  Medchemcomm       Date:  2018-06-14       Impact factor: 3.597

9.  The dopamine D3 receptor partial agonist CJB 090 inhibits the discriminative stimulus but not the reinforcing or priming effects of cocaine in squirrel monkeys.

Authors:  Cindy Achat-Mendes; Donna M Platt; Amy H Newman; Roger D Spealman
Journal:  Psychopharmacology (Berl)       Date:  2009-06-10       Impact factor: 4.530

10.  Design, synthesis, and evaluation of potent and selective ligands for the dopamine 3 (D3) receptor with a novel in vivo behavioral profile.

Authors:  Jianyong Chen; Gregory T Collins; Jian Zhang; Chao-Yie Yang; Beth Levant; James Woods; Shaomeng Wang
Journal:  J Med Chem       Date:  2008-09-12       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.